Urothelial Cancer patients are now enrolling into a Phase 2 trial for DN24-02, Dendreon Corporation’s investigational active cellular immunotherapy being evaluated for the treatment of HER2 positive cancer. The multicenter trial called Neu-ACT (NEU Active Cellular immunoTherapy) is expected to enroll approximately 180 patients to evaluate the safety and efficacy of DN24-02 as adjuvant therapy in patients with high risk HER2 positive invasive urothelial carcinoma, including bladder cancer, following surgical resection.
“We believe that our active cellular immunotherapy platform may have applications in the treatment of other cancers, and are pleased to offer patients and physicians access to DN24-02 through our Phase 2 Neu-ACT clinical trial,” said Mark Frohlich, M.D., executive vice president of research and development and chief medical officer. “Initiating a Phase 2 clinical trial to evaluate immunotherapy outside of the treatment of prostate cancer is a significant milestone for Dendreon, and we look forward to the outcome of this important study.”
Neu-ACT is a multicenter, open-label, Phase 2 study. Patients will be randomized to receive either the investigational product, DN24-02, or standard of care. The primary endpoint of the trial will be to evaluate overall survival between these two groups of patients. Other objectives of the study are to evaluate safety, disease-free survival, and immune response to treatment with DN24-02. Additional information is available at http://clinicaltrials.gov.
“Immunotherapy has great potential to offer breakthroughs in cancer care. In fact, bladder cancer recurrence rates have already seen a profound impact by immune manipulation. We are pleased to continue to lead this evolving field by participating in this Phase 2 trial clinical trial of DN24-02,” said John Corman, M.D., Medical Director of the Virginia Mason Cancer Institute in Seattle and clinical investigator for the Neu-ACT program. “Given the promise of immunotherapy, this is an important step forward for patients with this complex disease.”
Approximately 30 sites across the U.S. will participate in the Phase 2 Neu-ACT trial, including the following sites currently enrolling patients:
• Virginia Mason Medical Center, Seattle, Washington Contact: Kathryn Dahl, 206-341-0578, email@example.com Principal Investigator: John Corman, M.D.
• Columbia University Medical Center, New York, New York Contact: Katherine Resto-Garces, 212-304-5522, firstname.lastname@example.org Principal Investigator: Dan Petrylak, M.D.
• Fox Chase Cancer Center, Philadelphia, Pennsylvania Contact: Charlotte Cione, RN, 215-728-3614, Charlotte.Cione@fccc.edu Principal Investigator: Elizabeth Plimack, M.D.
• The Urology Center of Colorado, Denver, Colorado Contact: Candice Fortuna-Smith, 303-421-5783, email@example.com Principal Investigator: Lawrence Karsh, M.D.
• University of Chicago Medical Center, Chicago, Illinois Contact: Toni Mazurek, 773-834-0669 or 855-702-8222, firstname.lastname@example.org Principal Investigator: Peter O'Donnell, M.D.
• Indiana University, Indianapolis, Indiana Contact: Rhonda Loman, 317-274-0101, email@example.com Principal Investigator: Thomas Gardner, M.D.
• Duke University, Durham, North Carolina Contact: Trish Creel, 919-668-0635, firstname.lastname@example.org Principal Investigator: Michael Harrison, M.D.
• Providence Medical Center, Portland, Oregon Contact: Katrina Herz, 503-215-2617, Katrina.Herz@providence.org Contact: Scot Lary, 503-215-2604, John.Lary@providence.org Principal Investigator: Brendan Curti, M.D.